Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway

Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway

Chemoresistance is a major therapeutic obstacle in the treatment of human pancreatic ductal adenocarcinoma (PDAC). As an oxidative stress responsive transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2) regulates the expression of cytoprotective genes. Nrf2 not only plays a critic...

Full description

Bibliographic Details
Main Authors:	Yunjiang Zhou, Yang Zhou, Mengdi Yang, Keke Wang, Yisi Liu, Mingda Zhang, Yunjia Yang, Chenyu Jin, Rui Wang, Rong Hu
Format:	Article
Language:	English
Published:	Elsevier 2019-04-01
Series:	Redox Biology
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213231718310073

Similar Items

HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling
by: Yunjiang Zhou, et al.
Published: (2020-01-01)

Wogonin increases gemcitabine sensitivity in pancreatic cancer by inhibiting Akt pathway
by: Tianli Zhang, et al.
Published: (2022-12-01)

Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition
by: Venkatasubbaiah A. Venkatesha, et al.
Published: (2012-06-01)

Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
by: Amber Blaauboer, et al.
Published: (2020-09-01)

Pancreatic Cancer Chemoresistance to Gemcitabine
by: Manoj Amrutkar, et al.
Published: (2017-11-01)

YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine
by: Ling Zhou, et al.
Published: (2019-10-01)

Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
by: Nicolas Alejandro Fraunhoffer, et al.
Published: (2022-11-01)

Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer
by: Ru Chen, et al.
Published: (2017-08-01)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
by: Zhou Zhu, et al.
Published: (2023-10-01)

Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer
by: Jianhui Yang, et al.
Published: (2021-10-01)

Real-world outcomes of adjuvant gemcitabine gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
by: Sora Kang, et al.
Published: (2022-05-01)

PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine
by: Francisco Quiñonero, et al.
Published: (2022-11-01)

USP8 promotes gemcitabine resistance of pancreatic cancer via deubiquitinating and stabilizing Nrf2
by: Jing Cui, et al.
Published: (2023-10-01)

Carboxyamidotriazole-orotate inhibits proliferation and mitochondrial metabolism in human pancreatic cancer gemcitabine-resistant cell strain
by: CHEN Qiu-xia, YANG Li-xing, MA Rui, ZHAO Yong-jing, WANG Yu-cheng, JU Rui, GUO Lei
Published: (2022-04-01)

Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
by: Haorui Li, et al.
Published: (2023-10-01)

Dabigatran Potentiates Gemcitabine-Induced Growth Inhibition of Pancreatic Cancer in Mice
by: Kun Shi, et al.
Published: (2017-02-01)

Gemcitabine Combination Nano Therapies for Pancreatic Cancer
by: Kamalika Samanta, et al.
Published: (2019-11-01)

Forskolin sensitizes pancreatic cancer cells to gemcitabine via Stat3 and Erk1/2 inhibition
by: Michela Illiano, et al.
Published: (2017-06-01)

Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair
by: Tasneem Kausar, et al.
Published: (2015-10-01)

Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation.
by: Junjie Li, et al.
Published: (2018-01-01)

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
by: Guo ZY, et al.
Published: (2018-08-01)

High-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma
by: Lv W, et al.
Published: (2016-05-01)

Predictive modeling of in vivo response to gemcitabine in pancreatic cancer.
by: James J Lee, et al.
Published: (2013-01-01)

Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy
by: Erez Hasnis, et al.
Published: (2014-06-01)

Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors
by: Kentaro Minami, et al.
Published: (2015-03-01)

Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer
by: Chiorean EG, et al.
Published: (2018-05-01)

Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer
by: Yuhan Yang, et al.
Published: (2023-08-01)

An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma
by: Tianpeng Zhang, et al.
Published: (2023-12-01)

Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels
by: Concetta Panebianco, et al.
Published: (2021-04-01)

Pancreatic cancer cells spectral library by DIA-MS and the phenotype analysis of gemcitabine sensitivity
by: Ran Kong, et al.
Published: (2022-06-01)

DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
by: Fang Liu, et al.
Published: (2014-01-01)

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer
by: Azorsa David O, et al.
Published: (2009-06-01)

Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy
by: Saffiya Habib, et al.
Published: (2021-02-01)

Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma
by: Kaidong Liu, et al.
Published: (2022-08-01)

Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters
by: Ying-Si Wu, et al.
Published: (2021-04-01)

An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms
by: Hongjuan Yao, et al.
Published: (2022-09-01)

Extracellular Vesicles Inhibit the Response of Pancreatic Ductal Adenocarcinoma Cells to Gemcitabine and TRAIL Treatment
by: Ella Rimmer, et al.
Published: (2022-07-01)

Girdin Knockdown Increases Gemcitabine Chemosensitivity to Pancreatic Cancer by Modulating Autophagy
by: Sheng Wang, et al.
Published: (2021-03-01)

Periplocin exerts antitumor activity by regulating Nrf2-mediated signaling pathway in gemcitabine-resistant pancreatic cancer cells
by: Eun Seo Bae, et al.
Published: (2023-01-01)

Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine
by: Nannan Song, et al.
Published: (2023-08-01)